Paragon Care Limited (ASX:PGC)
Australia · Delayed Price · Currency is AUD | Market Cap | 248.30M -65.9% |
| Revenue (ttm) | 3.67B +8.5% |
| Net Income | -13.93M |
| EPS | -0.01 |
| Shares Out | 1.66B |
| PE Ratio | n/a |
| Forward PE | 9.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 153,912 |
| Average Volume | 481,656 |
| Open | 0.1450 |
| Previous Close | 0.1500 |
| Day's Range | 0.1400 - 0.1500 |
| 52-Week Range | 0.1400 - 0.4300 |
| Beta | 1.42 |
| RSI | 36.15 |
| Earnings Date | May 26, 2026 |
About Paragon Care
Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health and aged care markets in Australia, New Zealand, and internationally. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and pro... [Read more]
Financial Performance
In fiscal year 2025, Paragon Care's revenue was 3.61 billion, an increase of 21.68% compared to the previous year's 2.97 billion. Earnings were 20.57 million, an increase of 151.52%.
Financial StatementsNews
Paragon Care Ltd (ASX:PGC) (Q1 2026) Earnings Call Highlights: Resilient Performance Amidst ...
Paragon Care Ltd (ASX:PGC) (Q1 2026) Earnings Call Highlights: Resilient Performance Amidst Challenges
Half Year 2026 Paragon Care Ltd Earnings Call Transcript
Half Year 2026 Paragon Care Ltd Earnings Call Transcript
Paragon Care Earnings Call Transcript: H1 2026
Underlying revenue reached AUD 1.9 billion with EBITDA of AUD 49 million, while statutory results were impacted by a full provision for Infinity Group debt. Strong organic growth in Asia and contract logistics offset challenges, and full-year guidance is reaffirmed.
Paragon Care Quarterly report: H1 2026
Paragon Care has published its H1 2026 quarterly earnings report on February 24, 2026.
Paragon Care Slides: H1 2026
Paragon Care has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 24, 2026.
Paragon Care Earnings Call Transcript: H2 2025
Revenue grew 8.3% to $3.6 billion and underlying EBITDA rose 3% to $95.2 million, driven by strong Asia-Pacific and pharmacy performance. Integration synergies of $5 million were achieved, with $12 million targeted for FY 2026, and a $400 million refinancing improved capital flexibility.
Paragon Care Annual report: H2 2025
Paragon Care has published its H2 2025 annual report on August 26, 2025.
Paragon Care Slides: H2 2025
Paragon Care has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 26, 2025.
Paragon Care Earnings Call Transcript: H2 2024
The merger created a diversified healthcare business with FY24 pro forma revenue of AUD 3.3 billion and EBITDA of AUD 91 million. Integration is progressing, with cost synergies and organic growth prioritized, despite challenges in the Australian market.